
    
      Phase 3, Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous
      Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body
      Weight, Food-related Behavior, and Safety Over 6 Months
    
  